[ET Net News Agency, 27 September 2021] Akeso, Inc. (09926) said the company's
self-developed innovative drug candidate, IL-4R monoclonal antibody (research and
development code: AK120), was approved and agreed by the Food and Drug Administration of
the United States to initiate a global phase II clinical study for the treatment of
moderate-to-severe atopic dermatitis.
This is a multi-centre, randomized, double-blind, placebo-controlled, parallel, dosage
exploration phase II clinical trial to evaluate the efficacy and safety of AK120 in adult
subjects with moderate-to-severe atopic dermatitis.
AK120 is a novel drug targeting IL-4R of autoimmune treatment diseases independently
developed by the company. AK120 is intended to be used for the treatment of atopic
dermatitis, asthma and other allergic diseases. AK120 clinically treats allergic
autoimmune diseases by blocking the biological activities of dual cytokines IL-4 and
IL-13. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09926 AKESO
Nominal 
48.600 +1.150 (+2.424%) Others
27/09/2021 10:14
Akeso (09926) drug candidate gets clinical trial approval
| Remark: | Real time quote last updated: 25/04/2024 12:55 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |